A randomized trial of in-hospital initiation of an SGLT2 inhibitor in patients with heart failure missed its endpoint, but a ...

Over 3 years, SGLT2 inhibitors were safely associated with a nearly one third reduction in the risk for serious liver events.

Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), ...

In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. As far as SGLT2 inhibitors for first-line therapy in ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...

Compared with placebo, SGLT2 inhibitors reduced heart failure hospitalizations among patients with history of myocardial infarction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors may ...

A symposium on the new drug class, SGLT2 inhibitors, drew plenty of interest from attendees at the American Diabetes Association meeting in San Francisco. SGLT2 inhibitors have gained notice, both for ...

Patients with type 2 diabetes who receive sodium-glucose transport protein 2 inhibitors may have a lower risk for gout compared with those using dipeptidyl peptidase 4 inhibitors, according to data ...